Advertisement

Radiotherapy and Medical Treatment

  • Ester OrlandiEmail author
  • Domenico Romanello
  • Donata Galbiati
  • Lisa Licitra
Chapter

Abstract

Sinonasal cancers (SNCs) represent 3–5% of all head and neck carcinomas and less than 1% of all tumors. The majority of sinonasal tumors has epithelial origin and is generally diagnosed at advanced stages. Multimodal approaches, including chemotherapy and loco-regional approaches, notably surgery and/or radiotherapy (RT), are the mainstay of treatment of locally advanced disease. In particular, RT is a cornerstone in the treatment of this pathology, either in a definitive setting for unresectable disease or in a postoperative one, with a role in recurrent disease as well. The employment of high conformal radiation techniques, such as intensity-modulated radiation therapy or charged particle therapy, proton or carbon ion therapy, may improve outcome and reduce late effects. With regard to chemotherapy, as it occurs in a potentially curable disease, the choice of systemic treatments is tailored on the single patient global performance status, and it is histology driven.

The present chapter reports the evidences available in the literature on the role of RT and chemotherapy and targeted therapy in the management of SNCs.

Keywords

Intensity-modulated radiotherapy (IMRT) Proton therapy Carbon ion therapy Chemotherapy Toxicity 

References

  1. 1.
    Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34:877.  https://doi.org/10.1002/hed.21830.CrossRefPubMedGoogle Scholar
  2. 2.
    Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol. 2014;11(8):460–72.  https://doi.org/10.1038/nrclinonc.2014.97.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Duprez F, Madani I, Morbée L, et al. IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys. 2012;83(1):252–9.  https://doi.org/10.1016/j.ijrobp.2011.06.1977.CrossRefPubMedGoogle Scholar
  4. 4.
    Marta GN, Silva V, De Andrade CH, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9–15.  https://doi.org/10.1016/j.radonc.2013.11.010.CrossRefPubMedGoogle Scholar
  5. 5.
    Alonso-Basanta M, Lustig RA, Kennedy DW. Proton beam therapy in skull base pathology. Otolaryngol Clin N Am. 2011;44(5):1173–83.  https://doi.org/10.1016/j.otc.2011.08.012.CrossRefGoogle Scholar
  6. 6.
    Ansa B, Goodman M, Ward K, et al. Paranasal sinus squamous cell carcinoma incidence and survival based on surveillance, epidemiology, and end results data, 1973 to 2009. Cancer. 2013;119(14):2602–10.  https://doi.org/10.1002/cncr.28108.CrossRefPubMedGoogle Scholar
  7. 7.
    Nicolai P, Castelnuovo P, Lombardi D, et al. Role of endoscopic surgery in the management of selected malignant epithelial neoplasms of the naso-ethmoidal complex. Head Neck. 2007;29(12):1075–82.  https://doi.org/10.1002/hed.20636.CrossRefPubMedGoogle Scholar
  8. 8.
    Seong SY, Hyun DW, Kim YS, et al. Treatment outcomes of sinonasal adenoid cystic carcinoma: 30 cases from a single institution. J Craniomaxillofac Surg. 2014;42(5):e171–5.  https://doi.org/10.1016/j.jcms.2013.08.002.CrossRefPubMedGoogle Scholar
  9. 9.
    Hu YH, Tu GY, Qi YQ, et al. Comparison of pre- and postoperative radiation in the combined treatment of carcinoma of maxillary sinus. Int J Radiat Oncol Biol Phys. 1982;8(6):1045–9.CrossRefGoogle Scholar
  10. 10.
    Sisson GAS, Toriumi DM, Atiyah RA. Paranasal sinus malignancy: a comprehensive update. Laryngoscope. 1989;99(2):143–50.  https://doi.org/10.1288/00005537-198902000-00005.CrossRefPubMedGoogle Scholar
  11. 11.
    Waldron J, Witterick I. Paranasal sinus cancer: caveats and controversies. World J Surg. 2003;27(7):849–55.  https://doi.org/10.1007/s00268-003-7111-8.CrossRefPubMedGoogle Scholar
  12. 12.
    Bristol IJ, Ahamad A, Garden AS, et al. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys. 2007;68(3):719–30.  https://doi.org/10.1016/j.ijrobp.2007.01.032.CrossRefPubMedGoogle Scholar
  13. 13.
    Guan X, Wang X, Liu Y, Hu C, Zhu G. Lymph node metastasis in sinonasal squamous cell carcinoma treated with IMRT/3D-CRT. Oral Oncol. 2013;49(1):60–5.  https://doi.org/10.1016/j.oraloncology.2012.07.009.CrossRefPubMedGoogle Scholar
  14. 14.
    Ganly I, Patel S, Bilsky M, Shah J, Kraus D. Complications of craniofacial resection for malignant tumors of the skull base: report of an international collaborative study. Otolaryngol Head Neck Surg. 2009;140:218–23.CrossRefGoogle Scholar
  15. 15.
    Duthoy W, Boterberg T, Claus F, et al. Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer. 2005;104:71.  https://doi.org/10.1002/cncr.21100.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting-the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007;67(3):691–702.  https://doi.org/10.1016/j.ijrobp.2006.09.023.CrossRefPubMedGoogle Scholar
  17. 17.
    Orlandi E, Giandini T, Iannacone E, et al. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. Radiother Oncol. 2014;113(2):260–6.  https://doi.org/10.1016/j.radonc.2014.11.024.CrossRefPubMedGoogle Scholar
  18. 18.
    Lindeman P, Eklund U, Petruson B. Survival after surgical treatment in maxillary neoplasms of epithelial origin. J Laryngol Otol. 1987;101(6):564–8.CrossRefGoogle Scholar
  19. 19.
    Roa WH, Hazuka MB, Sandler HM, et al. Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses. Int J Radiat Oncol Biol Phys. 1994;28(4):857–65.CrossRefGoogle Scholar
  20. 20.
    Pommier P, Ginestet C, Sunyach M, et al. Conformal radiotherapy for paranasal sinus and nasal cavity tumors: three-dimensional treatment planning and preliminary results in 40 patients. Int J Radiat Oncol Biol Phys. 2000;48(2):485–93.CrossRefGoogle Scholar
  21. 21.
    Gabriele AM, Airoldi M, Garzaro M, et al. Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori. 2008;94(3):320–6.  https://doi.org/10.1177/030089160809400306.CrossRefPubMedGoogle Scholar
  22. 22.
    Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15(9):1027–38.  https://doi.org/10.1016/S1470-2045(14)70268-2.CrossRefPubMedGoogle Scholar
  23. 23.
    Mock U, Georg D, Bogner J, Auberger T, Pötter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:147–54.  https://doi.org/10.1016/S0360-3016(03)01452-4.CrossRefPubMedGoogle Scholar
  24. 24.
    Zenda S, Kohno R, Kawashima M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2011;81(5):1473–8.  https://doi.org/10.1016/j.ijrobp.2010.08.009.CrossRefPubMedGoogle Scholar
  25. 25.
    Truong MT, Kamat UR, Liebsch NJ, et al. Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck. 2009;31:1297.  https://doi.org/10.1002/hed.21092.CrossRefPubMedGoogle Scholar
  26. 26.
    Miyawaki D, Murakami M, Demizu Y, et al. Brain injury after proton therapy or carbon ion therapy for head-and-neck cancer and skull base tumors. Int J Radiat Oncol Biol Phys. 2009;75:378.  https://doi.org/10.1016/j.ijrobp.2008.12.092.CrossRefPubMedGoogle Scholar
  27. 27.
    Claus F, De Gersem W, De Wagter C, et al. An implementation strategy for IMRT of ethmoid sinus cancer with bilateral sparing of the optic pathways. Int J Radiat Oncol Biol Phys. 2001;51(2):318–31.  https://doi.org/10.1016/S0360-3016(01)01627-3.CrossRefPubMedGoogle Scholar
  28. 28.
    Cantù G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg. 2008;134(2):170–7.  https://doi.org/10.1001/archoto.2007.30.CrossRefPubMedGoogle Scholar
  29. 29.
    Kraus DH, Maghami E. Cancer of the nasal cavity and paranasal sinuses. Expert Rev Anticancer Ther. 2004;4(3):411–24.  https://doi.org/10.1586/14737140.4.3.411.CrossRefPubMedGoogle Scholar
  30. 30.
    Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys. 2007;69(1):141–7.  https://doi.org/10.1016/j.ijrobp.2007.02.031.CrossRefPubMedGoogle Scholar
  31. 31.
    Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008;72(3):763–9.  https://doi.org/10.1016/j.ijrobp.2008.01.038.CrossRefPubMedGoogle Scholar
  32. 32.
    Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006;78(3):306–12.  https://doi.org/10.1016/j.radonc.2006.02.003.CrossRefPubMedGoogle Scholar
  33. 33.
    Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–8.  https://doi.org/10.1002/hed.20697.CrossRefPubMedGoogle Scholar
  34. 34.
    Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30):4800–5.  https://doi.org/10.1200/JCO.2006.07.9194.CrossRefPubMedGoogle Scholar
  35. 35.
    Ozyigit G, Cengiz M, Hurmuz P, et al. Robotic stereotactic radiosurgery in patients with nasal cavity and paranasal sinus tumors. Technol Cancer Res Treat. 2014;13(5):409–13.  https://doi.org/10.7785/tcrtexpress.2013.600264.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Iwata H, Tatewaki K, Inoue M, Yokota N, Sato K, Shibamoto Y. Salvage stereotactic reirradiation using the CyberKnife for the local recurrence of nasal or paranasal carcinoma. Radiother Oncol. 2012;104(3):355–60.  https://doi.org/10.1016/j.radonc.2012.01.017.CrossRefPubMedGoogle Scholar
  37. 37.
    Jiang GL, Ang KK, Peters LJ, Wendt CD, Oswald MJ, Goepfert H. Maxillary sinus carcinomas: natural history and results of postoperative radiotherapy. Radiother Oncol. 1991;21:193.  https://doi.org/10.1016/0167-8140(91)90037-H.CrossRefPubMedGoogle Scholar
  38. 38.
    Karim AB, Kralendonk JH, Njo KH, Tabak JM, Elsenaar WH, van Balen AT. Ethmoid and upper nasal cavity carcinoma: treatment, results and complications. Radiother Oncol. 1990;19(2):109–20.CrossRefGoogle Scholar
  39. 39.
    Wiegner EA, Daly ME, Murphy JD, et al. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2012;83:243–51.  https://doi.org/10.1016/j.ijrobp.2011.05.044.CrossRefPubMedGoogle Scholar
  40. 40.
    Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck. 2002;24(9):821–9.  https://doi.org/10.1002/hed.10143.CrossRefPubMedGoogle Scholar
  41. 41.
    Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys. 1994;30(4):775–80.  https://doi.org/10.1016/0360-3016(94)90348-4.CrossRefPubMedGoogle Scholar
  42. 42.
    Takeda A, Shigematsu N, Suzuki S, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys. 1999;44(3):599–605.  https://doi.org/10.1016/S0360-3016(99)00057-7.CrossRefPubMedGoogle Scholar
  43. 43.
    Hawkins RB, Wynstra JH, Pilepich MV, Fields JN. Carcinoma of the nasal cavity—results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 1988;15(5):1129–33.  https://doi.org/10.1016/0360-3016(88)90194-0.CrossRefPubMedGoogle Scholar
  44. 44.
    Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007;67(1):151–7.  https://doi.org/10.1016/j.ijrobp.2006.07.1389.CrossRefPubMedGoogle Scholar
  45. 45.
    Lorusso P, Tapazoglou E, Kish JA, et al. Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. Cancer. 1988;62(1):1–5.  https://doi.org/10.1002/1097-0142(19880701)62:1<1::AID-CNCR2820620102>3.0.CO;2-F.CrossRefPubMedGoogle Scholar
  46. 46.
    Björk-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. Cancer. 1992;70:2615.  https://doi.org/10.1002/1097-0142(19921201)70:11<2615::AID-CNCR2820701108>3.0.CO;2-G.CrossRefPubMedGoogle Scholar
  47. 47.
    Lee MM, Vokes EE, Rosen A, Witt ME, Weichselbaum RR, Haraf DJ. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999;42:327.  https://doi.org/10.1016/S0360-3016(98)80506-3.CrossRefGoogle Scholar
  48. 48.
    Licitra L, Locati LD, Cavina R, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14:367–72.  https://doi.org/10.1093/annonc/mdg113.CrossRefPubMedGoogle Scholar
  49. 49.
    Hanna EY, Cardenas AD, DeMonte F, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011;137:78–81.  https://doi.org/10.1001/archoto.2010.231.CrossRefPubMedGoogle Scholar
  50. 50.
    Chopra S, Kamdar DP, Cohen DS, et al. Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity. Laryngoscope. 2017;127(4):855–61.  https://doi.org/10.1002/lary.26228.CrossRefPubMedGoogle Scholar
  51. 51.
    Papadimitrakopoulou VA, Ginsberg LE, Garden AS, et al. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003;98(10):2214–23.  https://doi.org/10.1002/cncr.11771.CrossRefPubMedGoogle Scholar
  52. 52.
    Samant S, Robbins KT, Vang M, Wan J, Robertson J. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg. 2004;130(8):948–55.  https://doi.org/10.1001/archotol.130.8.948.CrossRefPubMedGoogle Scholar
  53. 53.
    Homma A, Sakashita T, Yoshida D, et al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer. 2013;109(12):2980–6.  https://doi.org/10.1038/bjc.2013.663.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg. 2012;147(1):7–14.  https://doi.org/10.1177/0194599812440932.CrossRefPubMedGoogle Scholar
  55. 55.
    Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112:1450.  https://doi.org/10.1097/00005537-200208000-00023.CrossRefPubMedGoogle Scholar
  56. 56.
    Mourad WF, Hauerstock D, Shourbaji RA, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol. 2013;36:584–8.  https://doi.org/10.1097/COC.0b013e31825eb3a5.CrossRefPubMedGoogle Scholar
  57. 57.
    Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih LA. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck. 2004;26(5):435–41.  https://doi.org/10.1002/hed.10396.CrossRefPubMedGoogle Scholar
  58. 58.
    Likhacheva A, Rosenthal D, Hanna E, Kupferman M, Demonte F, El-Naggar A. Sinonasal neuroendocrine carcinoma: Impact of differentiation status on response and outcome. Head Neck Oncol. 2011;3(1):32.  https://doi.org/10.1186/1758-3284-3-32.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Rosenthal DI, Barker JL, El-Naggar AK, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004;101(11):2567–73.  https://doi.org/10.1002/cncr.20693.CrossRefPubMedGoogle Scholar
  60. 60.
    Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract: results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623–34.  https://doi.org/10.1002/cncr.10537.CrossRefGoogle Scholar
  61. 61.
    Licitra L, Suardi S, Bossi P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol. 2004;22(24):4901–6.  https://doi.org/10.1200/JCO.2004.05.071.CrossRefPubMedGoogle Scholar
  62. 62.
    Bossi P, Perrone F, Miceli R, et al. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncol. 2013;49(5):413–9.  https://doi.org/10.1016/j.oraloncology.2012.12.011.CrossRefPubMedGoogle Scholar
  63. 63.
    McElroy EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998;42(5):1023–7. ; discussion 1027–1028.  https://doi.org/10.1097/00006123-199805000-00040.CrossRefPubMedGoogle Scholar
  64. 64.
    Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132(2):134–8.  https://doi.org/10.1001/archotol.132.2.134.CrossRefPubMedGoogle Scholar
  65. 65.
    Porter AB, Bernold DM, Giannini C, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neuro-Oncol. 2008;90(2):201–4.  https://doi.org/10.1007/s11060-008-9645-y.CrossRefGoogle Scholar
  66. 66.
    Bell D, Saade R, Roberts D, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51–9.  https://doi.org/10.1007/s12105-014-0547-3.CrossRefPubMedGoogle Scholar
  67. 67.
    Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck. 2000;22(6):550–8.  https://doi.org/10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0.CrossRefPubMedGoogle Scholar
  68. 68.
    Stathis A, Zucca E, Bekradda M, et al. Clinical response of carcinomas harboring the BRD4–NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6(5):492–500.  https://doi.org/10.1158/2159-8290.CD-15-1335.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24(17):2673–8.  https://doi.org/10.1200/JCO.2005.05.3025.CrossRefPubMedGoogle Scholar
  70. 70.
    Jaspers HCJ, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29(16):e473–6.  https://doi.org/10.1200/JCO.2010.32.8351.CrossRefPubMedGoogle Scholar
  71. 71.
    Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2016;38(5):724–31.  https://doi.org/10.1002/hed.23940.CrossRefPubMedGoogle Scholar
  72. 72.
    Bossi P, Saba NF, Vermorken JB, et al. The role of systemic therapy in the management of sinonasal cancer: a critical review. Cancer Treat Rev. 2015;41(10):836–43.  https://doi.org/10.1016/j.ctrv.2015.07.004.CrossRefPubMedGoogle Scholar
  73. 73.
    Thavaraj S. Human papillomavirus-associated neoplasms of the sinonasal tract and nasopharynx. Semin Diagn Pathol. 2016;33(2):104–11.  https://doi.org/10.1053/j.semdp.2015.09.011.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ester Orlandi
    • 1
    Email author
  • Domenico Romanello
    • 1
  • Donata Galbiati
    • 2
  • Lisa Licitra
    • 2
    • 3
  1. 1.Radiotherapy 2 UnitFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  2. 2.Head and Neck Medical Oncology UnitFondazione IRCCS IstitutoTumoriMilanItaly
  3. 3.University of MilanMilanItaly

Personalised recommendations